Trillium unveils CD47 clinical research priorities as investors await solid tumor data

Trillium Therapeutics is up against some stiff competition to become a leader in the new class of drugs called CD47, which turn off the “don’t eat me” signal transmitted by cancer cells, but CEO Jan Skvarka, Ph.D., believes his biotech’s data will stand for themselves.